Literature DB >> 16313899

Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.

Toshiaki Kume1, Mitsuhiro Sugimoto, Yuki Takada, Toshiaki Yamaguchi, Atsushi Yonezawa, Hiroshi Katsuki, Hachiro Sugimoto, Akinori Akaike.   

Abstract

We previously reported that donepezil, a central-type acetylcholinesterase inhibitor, showed neuroprotective action via alpha4-and alpha7-nicotinic acetylcholine receptors against glutamate neurotoxicity in rat cortical culture. The present study was performed to investigate whether the neuroprotective action of acetylcholinesterase inhibitors is accompanied by the alteration of expression and function of nicotinic receptors. Four days treatment with acetylcholinesterase inhibitors (10 microM) enhanced the nicotine-induced increase of the intracellular calcium concentration. Immunoblot analysis revealed that donepezil increased both alpha4 and alpha7 subunit proteins. Donepezil and galanthamine increased the number of cells expressing alpha4- and alpha7-nicotinic receptors in immunocytochemical analysis. We examined whether up-regulation of nicotinic receptors affected the neuroprotective action of acetylcholinesterase inhibitors. Under up-regulating conditions, donepezil and galanthamine exerted neuroprotective action at lower concentrations. These results suggest that donepezil and galanthamine up-regulate nicotinic receptors in cortical neurons, and that the up-regulation of nicotinic receptors may make cortical neurons more sensitive to the neuroprotective action of donepezil and galanthamine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313899     DOI: 10.1016/j.ejphar.2005.10.028

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Authors:  J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

2.  Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Journal:  Schizophr Res       Date:  2008-06-11       Impact factor: 4.939

3.  A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.

Authors:  Zhengping Zhang; Rong Chen; Wenji An; Chunmei Wang; Gaoyong Liao; Xiaoliang Dong; Aijing Bi; Zhimin Yin; Lan Luo
Journal:  Psychopharmacology (Berl)       Date:  2015-11-11       Impact factor: 4.530

4.  Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis.

Authors:  R B Gibbs; R Mauk; D Nelson; D A Johnson
Journal:  Horm Behav       Date:  2009-03-20       Impact factor: 3.587

5.  Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.

Authors:  Camryn Berk; Marwan Sabbagh
Journal:  Int J Alzheimers Dis       Date:  2011-12-01

Review 6.  Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders.

Authors:  Roberta Benfante; Simona Di Lascio; Silvia Cardani; Diego Fornasari
Journal:  Aging Clin Exp Res       Date:  2019-10-03       Impact factor: 3.636

Review 7.  Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.

Authors:  Steven D Buckingham; Andrew K Jones; Laurence A Brown; David B Sattelle
Journal:  Pharmacol Rev       Date:  2009-03-16       Impact factor: 25.468

Review 8.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

Review 9.  The role of zebrafish (Danio rerio) in dissecting the genetics and neural circuits of executive function.

Authors:  Matthew O Parker; Alistair J Brock; Robert T Walton; Caroline H Brennan
Journal:  Front Neural Circuits       Date:  2013-04-08       Impact factor: 3.492

10.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.